TREMFYA® (guselkumab) Subscription Options

REGISTER FOR UPDATES ABOUT TREMFYA^®!

You are registering to receive information that is intended for healthcare providers only. By submitting the information requested below, you certify that you are a healthcare provider.

The information you provide will be used by Janssen Biotech, Inc., our affiliates, and our service providers, to send you TREMFYA^®-related information. You may unsubscribe from these communications by following the instructions in the e-mail messages you receive. Our Privacy Policy governs the use of the information you provide. By providing the information and selecting the “Submit” button, you indicate that you read, understand, and agree to these terms.

All fields required.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

Adverse Reactions
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

067010-170208

TREMFYA^® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA^® is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA^® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA^® after physician approval and proper training.